Advanced Biotechnologies Inc (ABI) has significant expertise and capabilities in viral infectious diseases and in particular, herpesviruses: CMV, HSV-1, HSV-2, VZV, EBV, and HHV-6, HHV-7 & HHV-8. ABI has developed an extensive array of proprietary and/or patented reagents and diagnostic kits for the study of these viruses and has funded critical research and development on HHV-6, 7 & 8. These emerging viruses continue to generate intense academic and clinical interest. Our research, as well as the research of many other prominent scientists, suggests that HHV-6 and HHV-8 may be important human pathogens or co-factors in certain human diseases:

HHV-6

• Multiple Sclerosis (MS)
• Chronic Fatigue Syndrome (CFS)
• Transplant rejection/complications
• AIDS

HHV-8

• Kaposi's Sarcoma (KS)
• Lymphoma (body cavity B cell)

Virus to disease relationships need further study and to that end, ABI has devoted significant time, effort and resources on clinical studies of the above diseases and has assembled most of the critical reagents and collaborators to answer fundamental questions concerning these emerging viruses. ABI enjoys a leadership position in HHV-6, 7 & 8 in terms of extensive proprietary research and production experience, unique reagents and diagnostic kits, collaborations at prestigious institutions, significant publications and presentations, clinical specimen acquisitions and lead time in research findings.

ABI is now faced with the challenge and mandate to maintain and capitalize on its leadership position by securing the assistance of a major corporate partner to support and fund key research, clinical investigation, product development and marketing. ABI has submitted patent applications on various aspects of HHV-6, 7 & 8 based on our proprietary propagation and purification techniques and on ABI's ability to develop and refine sensitive reagents and diagnostic kits and ultimately therapeutics and vaccines. The potential applications and markets associated with these viruses are important and attractive and ABI intends to play a key role in their development.